405 related articles for article (PubMed ID: 26907642)
1. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
[TBL] [Abstract][Full Text] [Related]
5. NEWBORNS WITH KASABACH-MERRITT PHENOMENON-ASSOCIATED KAPOSIFORM HEMANGIOENDOTHELIOMA: A REPORT OF 6 CASES.
Benzar IM; Rebenkov SO; Levytskyi AF; Fedoniuk LY; Fomina LV; Sas LM; Stravskyy TY
Wiad Lek; 2020; 73(8):1785-1789. PubMed ID: 33055352
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
8. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
9. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
10. Anesthestic management of Kassabach-Meritt Phenomenon in an adult: case report.
Elkoundi A; Samali M; Kartite N; Tbouda M; Bensghir M; Haimeur C
BMC Anesthesiol; 2016 Nov; 16(1):109. PubMed ID: 27829366
[TBL] [Abstract][Full Text] [Related]
11. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
12. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals.
Croteau SE; Liang MG; Kozakewich HP; Alomari AI; Fishman SJ; Mulliken JB; Trenor CC
J Pediatr; 2013 Jan; 162(1):142-7. PubMed ID: 22871490
[TBL] [Abstract][Full Text] [Related]
13. Kaposiform hemangioendothelioma: current knowledge and future perspectives.
Ji Y; Chen S; Yang K; Xia C; Li L
Orphanet J Rare Dis; 2020 Feb; 15(1):39. PubMed ID: 32014025
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma.
Wang Z; Zheng C; Sun H; Yao W; Li K; Ma Y; Zheng S
Dermatology; 2020; 236(3):262-270. PubMed ID: 31896113
[TBL] [Abstract][Full Text] [Related]
15. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
16. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up.
Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2015 Apr; 62(4):577-80. PubMed ID: 25346262
[TBL] [Abstract][Full Text] [Related]
17. Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
Tlougan BE; Lee MT; Drolet BA; Frieden IJ; Adams DM; Garzon MC
J Pediatr Hematol Oncol; 2013 Nov; 35(8):618-22. PubMed ID: 23774156
[TBL] [Abstract][Full Text] [Related]
18. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Chiu YE; Drolet BA; Blei F; Carcao M; Fangusaro J; Kelly ME; Krol A; Lofgren S; Mancini AJ; Metry DW; Recht M; Silverman RA; Tom WL; Pope E
Pediatr Blood Cancer; 2012 Nov; 59(5):934-8. PubMed ID: 22648868
[TBL] [Abstract][Full Text] [Related]
19. Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.
Chan S; Cassarino DS
JAMA Dermatol; 2013 Nov; 149(11):1337-8. PubMed ID: 24005816
[No Abstract] [Full Text] [Related]
20. Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon.
Pati S; Das MK; Rana A; Das E; Sarkar S; Sherpa N; Datta S
Indian J Pediatr; 2021 Nov; 88(11):1142-1144. PubMed ID: 34106442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
